Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients - Long-term results of a phase II study

Cancer Investigation

Volumn 24, Issue 1, 2006, Pages 22-27

  Baur, Martina ^a,b,c   Fazeny Doerner, B ^d   Hudec, M ^d   Sevelda, P ^e   Salzer, H ^f   Dittrich, Christian ^a,b,c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Applied Cancer Research Institute for Translational Research Vienna   (Austria)

^c 3rd Medical Department Oncology   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e GENERAL HOSPITAL LINZ   (Austria)

^f Wilhelminenspital ^*  (Austria)

Author keywords

Advanced ovarian cancer; Ifosfamide; Mesna; Platinum pretreatment; Salvage therapy

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MESNA; METHOTREXATE; METOCLOPRAMIDE; MITOMYCIN C; ONDANSETRON; PLATINUM; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVOR; CLINICAL TRIAL; COMA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MONOTHERAPY; MYCOSIS; NEUROTOXICITY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; SINUS TACHYCARDIA; SKIN NECROSIS; SUPRAVENTRICULAR PREMATURE BEAT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IFOSFAMIDE; MESNA; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROTECTIVE AGENTS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32644458564     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500449595     Document Type: Article

References (28)

1. Markman, M.; Rathman, R.; Hakes, T.; Reichman, B.; Hoskins, W.; Rubin, S.; Jones, W.; Almadrones, L.; Lewis, J.L. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991, 9, 389-393.
2. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361, 2099-2106.
3. Salom, E.; Almeida, Z.; Mirhashemi, R. Management of recurrent ovarian cancer: evidence-based decisions. Curr. Opin. Oncol. 2002, 14, 519-527.
4. Bookman, M.A. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Sem. Oncol. 2002, 2, 20-31.
5. Sutton, G.P.; Blessing, J.A.; Homesley, H.D.; Berman, M.L.; Malfetano, J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 1989, 7, 1672-1676.
6. Sorensen, P.; Pfeiffer, P.; Bertelsen, K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol. Oncol. 1995, 5, 75-78.
7. Markman, M.; Hakes, T.; Reichman, B.; Lewis, J.L.; Rubin, S.; Jones, W.; Almadrones, L.; Pizzuto, F.; Hoskins, W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 1992, 10, 243-248.
8. Markman, M.; Kennedy, A.; Sutton, G. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gyn. Oncol. 1998, 70, 272-274.
9. Willemse, PHB.; v. d. Burg, MEL.; v.d. Gaast, A.; Neijt, JP.; ten Bokkel Huinink, WW.; Aalders, JG.; de Vries, EGE. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother. Pharmacol. 1990, 26 (Suppl), S5-S54.
10. Jungi, WF.; Sessa, C.; Engeler, V.; Forni, M.; Mangioni, C.; Keller, A.; Cavalli, F. Phase II trial with high-dose ifosfamide (IFO) + mesna in advanced pretreated ovarian cancer. Proc. ASCO 1985, 4, 115.
11. Dorval, T.; Soussain, C.; Beuzeboc, P.; Garcia-Giralt, E.; Jouve, M.; Livartowski, A.; Mosseri, V.; Palangie, T.; Scholl, S.; Sastre, X.; Pouillart, P. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J. Infus. Chemother. 1996, 6, 47-49.
12. Scarfone, G.; Villa, A.; Parazzini, F.; Sciatta, C.; Polverino, G.; Bolis, G. A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumor. 1999, 8, 217-219.
13. Teufel, G.; Pfleiderer, A. Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas. Geburtshilfe Frauenheilkd. 1976, 3, 274-279.
14. Falkson, G.; Falkson, H.C. Further experience with isophosphamide. Cancer Treat. Rep. 1976, 60, 955-957.
15. Brade, W.; Seeber, S.; Herdrich, K. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother. Pharmacol. 1986, 18, S1-S9.
16. Steger, G.; Dittrich, C.; Schlappack, O.; Mader, R.; Herold, C.; Brade, WP.; Keller, A.; Moser, K. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. Cancer Res. Clin. Oncol. 1988, 114, 602-604.
17. Monfardini, S.; Brunner, K.; Crowther, D.; Eckhardt, S.; Olive, D.; Tanneberger, S.; Veronesi, A.; Whitehouse, JMA.; Wittes, R. In Manual of Adult and Paediatric Medical Oncology. Monfardini, S.; Brunner, K.; Crowther, D.; Eckhardt, S.; Olive, D.; Tanneberger, S.; Veronesi, A.; Whitehouse, JMA.; Wittes, R.; Eds; Manual of Adult and Pediatric Medical Oncology, Springer Heidelberg, 1987, pp. 22-38.
18. NCI Common Toxicity Criteria. National Cancer Institute, Division of Cancer Treatment, 1988.
19. Di Leo, A.; Bajetta, E.; Biganzoli, L. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur. J. Cancer 1995, 31 (A), 2248-2254.
20. Maglietta, L.; Amoroso, D.; Buzzone, M. Paclitaxel plus ifosfamide in advanced ovarian cancer. Oncology 1997, 54, 102-107.
21. Gordon, AN.; Fleagle, JT.; Guthrie, D.; Parkin, DE.; Gore, ME.; Lacave, AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001, 19, 3312-3322.
22. Ten Bokkel Huinink, W.; Gore, M.; Carmichael, J.; Gordon, A.; Malfetano, J.; Hudson, I.; Broom, C.; Scarabelli, C.; Davidson, N.; Spanczynski, M.; Bolis, G.; Malmstrom, H.; Coleman, R.; Fields, SC.; Heron, JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997, 15, 2183-2193.
23. Malik, IA.; Mehboobali, N.; Iqbal, MP. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol. 1997, 39, 561-565.
24. Rose, PG.; Blessing, JA.; Mayer, AR.; Homesley HD. Prolonged oral etoposide as second line therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: a Gynecologic Oncology Group Study. Proc. ASCO 1996, 15, 282.
25. Abu-Rustum, N.R.; Aghajanian, C.; Barakat, R.R.; Fennelly, D.; Shapiro, F.; Spriggs, D. Salvage weekly paclitaxel in recurrent ovarian cancer. Sem. Oncol. 1997, 24(Suppl.), S15-62-S15-67.
26. Markman, M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Sem. Oncol. 2002, 29, 9-10.
27. Gore, M.; ten Bokkel Huinink, W.; Carmichael, J.; Gordon, A.; Davidson, N.; Coleman, R.; Spaczynski, M.; Heron, JF.; Bolis, G.; Malmstrom, H.; Malfetano, J.; Scarabelli, C.; Vennin, P.; Ross, G.; Fields, S.Z. Clinical evidence for topotecan-paclitaxel non-crossresistance in ovarian cancer. J. Clin. Oncol. 2001, 19, 1893-1900.
28. Sarosy, G. Ifosfamide-pharmacologic overview. Sem. Oncol. 1989, 16, 2-8.